Navigation Links
Avelas Biosciences Closes $6.85 Million in Series B Financing to Advance Real-Time Cancer Visualization Technology to Clinical Proof-of-Concept
Date:1/9/2014

SAN DIEGO, Jan. 9, 2014 /PRNewswire/ --  Avelas Biosciences announced today the closing of a $6.85 million tranche of a Series B financing round – bringing the total funds raised since inception to ~$14 million.  The funds will be used to support ongoing development of the Avelas Cancer Illuminator (ACI) candidate, AVB-620, through first-in-patient study. The financing was led by founding investor, Avalon Ventures, joined by new investors Torrey Pines Investment, WuXi AppTec, and an additional unnamed investor.

In conjunction with the financing, Avelas Biosciences has promoted Carmine Stengone to chief executive officer where he and Nikolay Savchuk, Ph.D., managing director for Torrey Pines Investment, will join the board of directors. Jay Lichter, Ph.D., managing partner for Avalon Ventures, has been appointed board chairman.  Kevin Kinsella and Timothy Scott will remain on the Avelas board of directors.

"ACI technology offers an objective and quantitative approach to oncologic surgical imaging that cannot be achieved using conventional techniques, which lack sensitivity and are prone to artifacts," said Dr. Lichter. "This new financing round will propel AVB-620 development one step closer to accurately visualizing cancer in real-time for patients."

Surgery is an important part of breast cancer management.  In addition to removal of the primary tumor, surgery is required for tissue biopsy and accurate cancer staging, which is critical for subsequent treatment decisions. Unfortunately, the current standard for evaluating these samples cannot be done in real-time and, therefore, often requires a second operation which exposes the patient to additional surgical risk and cost.  A means of determining the cancer status of tissue in real-time would represent a significant step forward in the management of early breast cancer.

AVB-620, a fluorescent peptide, delivers a real-time intraoperative cancer diagnosis in the form of a luminous map, providing surgeons with enough information to make a decision during the first surgery as opposed to waiting for the results of limited pathology reports. In preclinical testing, the in vivo accuracy of AVB-620 is >95%.

"AVB-620 will enable surgeons to identify cancerous tissue during the surgical procedure, addressing a key unmet need in the oncologic surgery space," said Carmine Stengone, CEO of Avelas. "This capability will allow surgeons to make real-time decisions that will improve patient treatment and lead to significant cost savings by reducing surgical time and the number of re-operations."

The ACI technology, founded by Nobel Prize winning scientist Roger Tsien, Ph.D., utilizes the increased activity of enzymes called proteases that occur in tumors and metastases. The fluorescent peptide illuminates in the presence of pathological protease activity, thereby marking the cancerous tissue. When used in conjunction with a fluorescence imaging camera system during surgery, a color-coded image showing cancerous tissue is superimposed onto the normal surgical view, providing the surgeon a map of the cancer location.

About Avelas Biosciences
Avelas Biosciences is a San Diego-based biotechnology company focused on developing fluorescent technologies that advance a new standard-of-care for cancer surgery. Its lead candidate, AVB-620, is expected to enter clinical studies in 2014. Avelas was founded by Avalon Ventures on technology from Nobel Prize winner Roger Tsien, Ph.D.  For additional information, please visit www.avelasbio.com.


'/>"/>
SOURCE Avelas Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
2. Sangamo BioSciences Announces Conference Call And Webcast To Discuss Global Collaboration with Biogen Idec to Develop Treatments for Hemoglobinopathies
3. Cardio3 BioSciences, a European biopharmaceutical company, now covered by Edison Investment Research
4. Proove Biosciences Successfully Presents Data and Exhibits at the Eastern Pain Association’s Annual Meeting in New York, New York
5. Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting
6. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
7. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI
8. Neurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference
9. Proove Biosciences CEO Brian Meshkin Wins 2013 Bridging the Gap Award by the Greater Baltimore Committee
10. Sangamo BioSciences Announces Presentation At The 25th Annual Piper Jaffray Healthcare Conference
11. Telomere Biosciences Announces: TELO-100 with T-Activator 150, a Breakthrough in Telomere Science and Age Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/9/2016)... in attendance control systems is proud to announce the introduction of fingerprint attendance control ... right employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
Breaking Biology News(10 mins):